Adc Therapeutics Sa (ADCT) - News Archive

ADC Therapeutics Expedites Growth with Strategic Employee Stock Option GrantsLAUSANNE, Switzerland ADC Therapeutics SA (NYSE: ADCT), a leading entity in the commercial-stage biopharmaceutical sector specializing in Anti...

ADC Therapeutics Expands Talent Pool with New Options Grants as It Strengthens Leadership in Antibody Drug ConjugatesIn an industry that thrives on innovation, ADC Therapeutics SA (NYSE: ADCT), a frontrunner in the deve...

ADC Therapeutics SA, a globally recognized leader in the field of antibody drug conjugates (ADCs), has recently made a significant announcement. On September 3, 2024, the Company granted options to purchase a total of 1...

ADC Therapeutics SA, a leading player in the field of antibody drug conjugates (ADCs), has recently made a significant announcement regarding the granting of options to three new employees. This induction plan aims to m...

In recent times, ADC Therapeutics SA (ADCT) has experienced a dip in its market performance, trailing behind the overall market. However, it is essential to analyze this temporary setback in the context of significant r...

Exploring the Success and Challenges of ADC Therapeutics: A Leader in Antibody Drug ConjugatesADC Therapeutics (ADCT) has emerged as a global leader and pioneer in the field of antibody drug conjugates (ADCs). With thei...

GlobalTech Corporation is excited to announce that its common stock, denoted as GLTK on the OTC market, will now be available for trading. This landmark move is expected to have a significant impact on the company s sha...

ADC Therapeutics SA Raises $105 Million in Underwritten Offering and Awards Stock Options to New EmployeesLausanne, Switzerland May 6, 2024 ADC Therapeutics SA (NYSE: ADCT), a leading biotechnology company focused on th...

CSIMarket.com is delighted to present groundbreaking findings from a Phase 2 clinical trial conducted by ADC Therapeutics. The trial investigates the efficacy of ZYNLONTA, a targeted antibody-drug conjugate (ADC), in pa...

ADC Therapeutics SA Announces Grants of Options to New Employees Under Inducement PlanLAUSANNE, Switzerland, May 01, 2024 - ADC Therapeutics SA (NYSE: ADCT) has recently made grants of options to purchase an aggregate o...

ADC Therapeutics, a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors, has recently provided updates on its ongoing...

ADC Therapeutics SA, a prominent biotechnology company revolutionizing the field of antibody-drug conjugates, has recently announced the granting of options to purchase an aggregate of 53,800 of its common shares to six...